BRCA1 and ovarian carcinoma: Following this, paired phase II studies were then carried out which confirmed cell killing effect and demonstrated dose response in BRCA1/2 mutant breast and ovarian cancers, with better patient outcomes observed for patients with platinum sensitive compared to platinum resistant disease [16,17].